Savara Inc Stock Today
| SVRA Stock | USD 3.41 0.05 1.49% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Savara is trading at 3.41 as of the 25th of November 2024, a 1.49 percent increase since the beginning of the trading day. The stock's open price was 3.36. Savara has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Savara Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of June 2017 | Category Healthcare | Classification Health Care |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company has 171.62 M outstanding shares of which 13.16 M shares are at this time shorted by private and institutional investors with about 12.36 trading days to cover. More on Savara Inc
Moving together with Savara Stock
| 0.8 | ME | 23Andme Holding | PairCorr |
| 0.73 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Savara Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Savara Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CEO | MBA JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSavara can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Savara's financial leverage. It provides some insight into what part of Savara's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Savara Inc (SVRA) is traded on NASDAQ Exchange in USA. It is located in 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047 and employs 37 people. Savara is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 576.64 M. Savara Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 171.62 M outstanding shares of which 13.16 M shares are at this time shorted by private and institutional investors with about 12.36 trading days to cover.
Savara Inc currently holds about 142.62 M in cash with (51.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25.
Check Savara Probability Of Bankruptcy
Ownership AllocationSavara Inc shows a total of 171.62 Million outstanding shares. The majority of Savara Inc outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Savara to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Savara Inc. Please pay attention to any change in the institutional holdings of Savara Inc as this could imply that something significant has changed or is about to change at the company. Also note that roughly two million ninety-three thousand seven hundred fifty-two invesors are currently shorting Savara expressing very little confidence in its future performance.
Check Savara Ownership Details
Savara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nantahala Capital Management, Llc | 2024-09-30 | 5.2 M | |
| Farallon Capital Management, L.l.c. | 2024-09-30 | 4.6 M | |
| State Street Corp | 2024-06-30 | 3.6 M | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 2.8 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.7 M | |
| Hhg Plc | 2024-06-30 | 2.3 M | |
| Altium Capital Management, Lp | 2024-09-30 | 1.6 M | |
| Fmr Inc | 2024-09-30 | 1.1 M | |
| Axa Sa | 2024-06-30 | 1.1 M | |
| Nea Management Company, Llc | 2024-06-30 | 24.5 M | |
| Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 14.6 M |
Savara Historical Income Statement
Savara Stock Against Markets
Savara Corporate Management
| Anne Erickson | IR Contact Officer | Profile | |
| Peter Clarke | Executive Operations | Profile | |
| Brian Maurer | Head Operations | Profile | |
| Charles LaPree | Senior Assurance | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Savara Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Savara. If investors know Savara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Savara listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Return On Assets (0.26) | Return On Equity (0.48) |
The market value of Savara Inc is measured differently than its book value, which is the value of Savara that is recorded on the company's balance sheet. Investors also form their own opinion of Savara's value that differs from its market value or its book value, called intrinsic value, which is Savara's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Savara's market value can be influenced by many factors that don't directly affect Savara's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Savara's value and its price as these two are different measures arrived at by different means. Investors typically determine if Savara is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Savara's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.